Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.
about
Immunotherapies targeting CD38 in Multiple Myeloma.Integration of Novel Agents into the Care of Patients with Multiple Myeloma.Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
P2860
Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Re-challenging with anti-CD38 ...... a feasible and safe approach.
@en
Re-challenging with anti-CD38 ...... a feasible and safe approach.
@nl
type
label
Re-challenging with anti-CD38 ...... a feasible and safe approach.
@en
Re-challenging with anti-CD38 ...... a feasible and safe approach.
@nl
prefLabel
Re-challenging with anti-CD38 ...... a feasible and safe approach.
@en
Re-challenging with anti-CD38 ...... a feasible and safe approach.
@nl
P2093
P2860
P50
P356
P1476
Re-challenging with anti-CD38 ...... a feasible and safe approach.
@en
P2093
Imran Khan
Johan Lund
Michael Chrobok
Tahamtan Ahmadi
P2860
P304
P356
10.1111/BJH.13776
P407
P577
2015-10-12T00:00:00Z